| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1359-6446(99)01393-8 |
| P698 | PubMed publication ID | 10481138 |
| P2093 | author name string | Lahana R | |
| P433 | issue | 10 | |
| P304 | page(s) | 447-448 | |
| P577 | publication date | 1999-10-01 | |
| P1433 | published in | Drug Discovery Today | Q3040085 |
| P1476 | title | How many leads from HTS? | |
| P478 | volume | 4 |
| Q30387229 | Advances in Nuclear Magnetic Resonance for Drug Discovery |
| Q34019272 | Application of NMR and molecular docking in structure-based drug discovery |
| Q33246077 | Assay concordance between SPA and TR-FRET in high-throughput screening |
| Q30875895 | Chemoinformatics methods for systematic comparison of molecules from natural and synthetic sources and design of hybrid libraries |
| Q78844336 | Chemoinformatics methods for systematic comparison of molecules from natural and synthetic sources and design of hybrid libraries |
| Q37729463 | Computational drug discovery |
| Q47889903 | Computer aided drug design and its application to the development of potential drugs for neurodegenerative disorders |
| Q34530440 | Discovery of a new class of inhibitors for the protein arginine deiminase type 4 (PAD4) by structure-based virtual screening |
| Q37118507 | Distributed Drug Discovery, Part 1: linking academia and combinatorial chemistry to find drug leads for developing world diseases |
| Q37296002 | Docking, virtual high throughput screening and in silico fragment-based drug design |
| Q73359223 | Drug discovery today - and tomorrow |
| Q35194765 | Drug research: myths, hype and reality |
| Q47750111 | Ensemble docking to difficult targets in early-stage drug discovery: Methodology and application to fibroblast growth factor 23. |
| Q46652869 | Further comparison of primary hit identification by different assay technologies and effects of assay measurement variability |
| Q51436316 | Higher order alchemical derivatives from coupled perturbed self-consistent field theory. |
| Q28548496 | Identification and Validation of a Potent Dual Inhibitor of the P. falciparum M1 and M17 Aminopeptidases Using Virtual Screening |
| Q35603833 | Identification and characterization of novel small-molecule inhibitors against hepatitis delta virus replication by using docking strategies. |
| Q36840592 | In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling |
| Q33309109 | Lessons learnt from assembling screening libraries for drug discovery for neglected diseases |
| Q29617403 | Ligand efficiency: a useful metric for lead selection |
| Q30788436 | Microchip-based high-throughput screening analysis of combinatorial libraries |
| Q28828257 | Nature's bounty - drug discovery from the sea |
| Q95784538 | New drug discovery techniques are not so revolutionary |
| Q84684181 | New molecular scaffolds for the design of Mycobacterium tuberculosis type II dehydroquinase inhibitors identified using ligand and receptor based virtual screening |
| Q34581581 | Physiologically-based pharmacokinetic simulation modelling. |
| Q31041742 | Predictive models for anti-tubercular molecules using machine learning on high-throughput biological screening datasets |
| Q34381519 | QSAR of phytochemicals for the design of better drugs. |
| Q73259559 | Quo vadis, biotech? (Part 1) |
| Q39675574 | Rapid activity prediction of HIV-1 integrase inhibitors: harnessing docking energetic components for empirical scoring by chemometric and artificial neural network approaches |
| Q33443633 | Recent advances in computer-aided drug design |
| Q35171811 | Review article: mitogen-activated protein kinases in chronic intestinal inflammation - targeting ancient pathways to treat modern diseases |
| Q39417388 | State-of-the-art and dissemination of computational tools for drug-design purposes: a survey among Italian academics and industrial institutions |
| Q30880493 | Strategies for discovering drugs from previously unexplored natural products |
| Q34175884 | Structure-based and ligand-based virtual screening of novel methyltransferase inhibitors of the dengue virus |
| Q35072850 | The current state of drug discovery and a potential role for NMR metabolomics |
| Q78026623 | The design of combinatorial libraries |
| Q34620026 | The future of plant drug discovery |
| Q38063813 | Translational PK-PD modeling in pain |
| Q38125903 | Triggers and cues that activate antibiotic production by actinomycetes |
| Q33378588 | VSDMIP: virtual screening data management on an integrated platform. |
| Q33247681 | Virtual ligand screening: strategies, perspectives and limitations |
| Q34626368 | Virtual screening of chemical libraries for drug discovery |
| Q30366496 | Virtual screening: an in silico tool for interlacing the chemical universe with the proteome. |
| Q73826148 | Who wants to be irrational? |
Search more.